Comparative Pharmacology
Head-to-head clinical analysis: FEMINONE versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMINONE versus STILPHOSTROL.
FEMINONE vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMINONE (progesterone) is a steroid hormone that binds to the progesterone receptor, modulating gene expression in target tissues. It transforms the endometrium from proliferative to secretory phase, reduces endometrial hyperplasia risk, and suppresses gonadotropin release via negative feedback.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
0.625 mg orally once daily
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 7-8 hours (range 5-12 h); clinical significance: steady-state reaches after ~2-3 days, necessitates daily dosing for contraceptive efficacy.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Feminone (norethindrone) is primarily excreted in urine (approximately 70-80% as metabolites, with <5% as unchanged drug) and feces (20-30%).
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen
Estrogen